Illumina, a leading biotechnology company, has announced a significant change in its executive team. The current Chief Financial Officer (CFO), Mr. Goswami, is set to depart from the company. He will be succeeded by a former executive from Summit Therapeutics, Mr. Dhingra.
Mr. Goswami has played a crucial role in Illumina's financial management during his tenure as CFO. His departure marks the end of an era for the company, as he moves on to pursue other opportunities.
